The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells

Journal of Diabetes and its Complications

Volumn 20, Issue 5, 2006, Pages 336-342

  Goya, Kayoko ^a   Sumitani, Satoru ^a   Otsuki, Michio ^a   Xu, Xin ^a   Yamamoto, Hiroyasu ^a   Kurebayashi, Shogo ^a   Saito, Hiroshi ^a   Kouhara, Haruhiko ^a   Kasayama, Soji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelium; Nitric oxide; Peroxisome proliferator activated receptor; Thiazolidinedione

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ALPHA TOCOPHEROL; GLITAZONE DERIVATIVE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TROGLITAZONE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; ENDOTHELIUM CELL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INSULIN RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURAL HOMOLOGY; UMBILICAL VEIN; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION; WESTERN BLOTTING;

ALPHA-TOCOPHEROL; ANALYSIS OF VARIANCE; CELLS, CULTURED; CHROMANS; ENDOTHELIAL CELLS; HUMANS; HYPOGLYCEMIC AGENTS; NITRIC OXIDE SYNTHASE TYPE III; PROSTAGLANDIN D2; RNA, MESSENGER; THIAZOLIDINEDIONES; UMBILICAL VEINS; UP-REGULATION; VASODILATION;

EID: 33747871378     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2005.08.003     Document Type: Article

References (52)

1. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., Digby J.E., Sewter C.P., Lazar M.A., Chatterjee V.K., and O'Rahilly S. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation 100 (1997) 3149-3153
2. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., and Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23 (2000) 1605-1611
3. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., Scott S., Rude R.K., and Hsueh W.A. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. Journal of Clinical Investigation 96 (1995) 354-360
4. Calnek D.S., Mazzella L., Roser S., Roman J., and Hart C.M. Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 23 (2003) 52-57
5. Calver A., Collier J., and Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. Journal of Clinical Investigation 90 (1992) 2548-2554
6. Cantello B.C., Cawthorne M.A., Cottam G.P., Duff P.T., Haigh D., Hindley R.M., Lister C.A., Smith S.A., and Thurlby P.L. [[omega-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. Journal of Medical Chemistry 37 (1994) 3977-3985
7. Cho D.H., Choi Y.J., Jo S.A., and Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: Evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ-dependent and PPAR γ-independent signaling pathways. Journal of Biological Chemistry 279 (2004) 2499-2506
8. Davies G.F., Khandelwal R.L., Wu L., Juurlink B.H., and Roesler W.J. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: A peroxisome proliferator-activated receptor-γ (PPARγ)-independent, antioxidant-related mechanism. Biochemical Pharmacology 62 (2001) 1071-1079
9. Davies G.F., McFie P.J., Khandelwal R.L., and Roesler W.J. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-γ expression in hepatocytes. Journal of Pharmacology and Experimental Therapeutics 300 (2002) 72-77
10. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone Jr. M.A., Shin W.S., and Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation 96 (1995) 60-68
11. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., and Vanhoutte P.M. Endothelial dysfunction in diabetes. British Journal of Pharmacology 130 (2000) 963-974
12. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., and Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 (1992) 879-887
13. 2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83 (1995) 802-812
14. Forstermann U., Closs E.I., Pollock J.S., Nakane M., Schwarz P., Gath I., and Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 23 (1994) 1121-1131
15. Fujishima S., Ohya Y., Nakamura Y., Onaka U., Abe I., and Fujishima M. Troglitazone, an insulin sensitizer, increases forearm blood flow in humans. American Journal of Hypertension 11 (1998) 1134-1137
16. Ghazzi M.N., Perez J.E., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., and Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46 (1997) 433-439
17. Inoue I., Katayama S., Takahashi K., Negishi K., Miyazaki T., Sonoda M., and Komoda T. Troglitazone has a scavenging effect on reactive oxygen species. Biochemical and Biophysical Research Communications 235 (1997) 113-116
18. Jackson S.M., Parhami F., Xi X.P., Berliner J.A., Hsueh W.A., Law R.E., and Demer L.L. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arteriosclerosis, Thrombosis, and Vascular Biology 19 (1999) 2094-2104
19. Jiang C., Ting A.T., and Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
20. Joannides R., Haefeli W.E., Linder L., Richard V., Bakkali E.H., Thuillez C., and Luscher T.F. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 92 (1995) 1314-1319
21. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., and Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 88 (1993) 2510-2516
22. Kawasaki J., Hirano K., Nishimura J., Fujishima M., and Kanaide H. Mechanisms of vasorelaxation induced by troglitazone, a novel antidiabetic drug, in the porcine coronary artery. Circulation 98 (1998) 2446-2452
23. Kliewer S.A., Forman B.M., Blumberg B., Ong E.S., Borgmeyer U., Mangelsdorf D.J., Umesono K., and Evans R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 91 (1994) 7355-7359
24. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83 (1995) 813-819
25. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., and Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 86 (2001) 3452-3456
26. Kotchen T.A., Zhang H.Y., Reddy S., and Hoffmann R.G. Effect of pioglitazone on vascular reactivity in vivo and in vitro. American Journal of Physiology 270 (1996) R660-R666
27. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). Journal of Biological Chemistry 270 (1995) 12953-12956
28. Loi C.M., Alvey C.W., Vassos A.B., Randinitis E.J., Sedman A.J., and Koup J.R. Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites. Journal of Clinical Pharmacology 39 (1999) 920-926
29. Loscalzo J. Nitric oxide and vascular tone. New England Journal of Medicine 333 (1995) 251-253
30. Lowell B.B. PPARγ: An essential regulator of adipogenesis and modulator of fat cell function. Cell 99 (1999) 239-242
31. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circulation Research 83 (1998) 1097-1103
32. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R., Andrews J.W., and Hayes J.R. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35 (1992) 771-776
33. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. New England Journal of Medicine 329 (1993) 2002-2012
34. Murao K., Imachi H., Momoi A., Sayo Y., Hosokawa H., Sato M., Ishida T., and Takahara J. Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Letters 454 (1999) 27-30
35. Newaz M.A., Nawal N.N., Rohaizan C.H., Muslim N., and Gapor A. α-Tocopherol increased nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats. American Journal of Hypertension 12 (1999) 839-844
36. Nolan J.J., Jones N.P., Patwardhan R., and Deacon L.F. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus. Diabetic Medicine 17 (2000) 287-294
37. Ogihara T., Rakugi H., Ikegami H., Mikami H., and Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. American Journal of Hypertension 8 (1995) 316-320
38. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferators-activated receptor agonists. Journal of Clinical Investigation 106 (2000) 467-472
39. Pasceri V., Wu H.D., Willerson J.T., and Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101 (2000) 235-238
40. Petersen K.F., Krssak M., Inzucchi S., Cline G.W., Dufour S., and Shulman G.I. Mechanism of troglitazone action in type 2 diabetes. Diabetes 49 (2000) 827-831
41. Ramasamy S., Drummond G.R., Ahn J., Storek M., Pohl J., Parthasarathy S., and Harrison D.G. Modulation of expression of endothelial nitric oxide synthase by nordihydroguaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Molecular Pharmacology 56 (1999) 116-123
42. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
43. Rodriguez J.A., Grau A., Eguinoa E., Nespereira B., Perez-Ilzarbe M., Arias R., Belzunce M.S., Paramo J.A., and Martinez-Caro D. Dietary supplementation with vitamins C and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis 165 (2002) 33-40
44. Sakamoto J., Kimura H., Moriyamam S., Odaka H., Momose Y., Sugiyama Y., and Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochemical and Biophysical Research Communications 278 (2000) 704-711
45. Schwartz S., Raskin P., Fonseca V., and Graveline J.F. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. New England Journal of Medicine 338 (1988) 861-866
46. Sidhu J.S., Kaposzta Z., Markus H.S., and Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 24 (2004) 930-934
47. 2+ currents and not endothelial nitric oxide production. Diabetes 46 (1997) 659-664
48. Sugawara A., Takeuchi K., Uruno A., Ikeda Y., Arima S., Sato K., Kudo M., Taniyama Y., and Ito S. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes. Hypertension Research 24 (2001) 229-233
49. Sung B.H., Izzo Jr. J.L., Dandona P., and Wilson M.F. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension 34 (1999) 83-88
50. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., and Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106 (2002) 1652-1658
51. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., and Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology 27 (1996) 567-574
52. Zierath J.R., Ryder J.W., Doebber T., Woods J., Wu M., Ventre J., Li Z., McCrary C., Berger J., Zhang B., and Moller D.E. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology 139 (1998) 5034-5041